Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 4/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872872 | 0.97 | MKNK1 (0.45) | MKNK1MKNK2PIM1HTR2CHRH4 | |
| SCHEMBL5872880 | 0.93 | CYP2C9 (0.43) | PIM1HTR2CCYP2C9KDM5ADRD2 | |
| SCHEMBL5795447 | 0.88 | PIM1 (0.41) | PIM1HTR2CHRH4DRD2DRD3 | |
| SCHEMBL5773190 | 0.88 | HTR2C (0.45) | PIM1HTR2CHPGD | |
| SCHEMBL5873067 | 0.87 | MKNK1 (0.43) | MKNK1MKNK2PIM1HTR2CHRH4 | |
| SCHEMBL5872958 | 0.86 | MKNK1 (0.43) | MKNK1MKNK2PIM1HTR2CPIM3 | |
| SCHEMBL5873211 | 0.86 | CYP2C9 (0.48) | PIM1HRH4CYP2C9KDM5A | |
| SCHEMBL5774021 | 0.85 | NPC1 (0.44) | PIM1CYP2C9PARP1DRD2DRD3 | |
| SCHEMBL5769674 | 0.85 | PIM1 (0.40) | PIM1CYP2C9KDM5A | |
| SCHEMBL5872987 | 0.85 | MKNK1 (0.44) | MKNK1MKNK2PIM1HTR2CPIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | MKNK1 2151/4885MKNK2 2127/4885PIM1 1909/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | MKNK1 2151/4885MKNK2 2127/4885PIM1 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.